Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Wall Street expects a year-over-year decline in earnings on higher revenues when Werewolf Therapeutics, Inc. (HOWL) reports results for the quarter ended March 2025. While this widely-known consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback